Phase I study of RP 49532A, a new protein-synthesis inhibitor, in patients with advanced refractory solid tumors. - Catimel,G.; Coquard,R.; Guastalla,J.P.; Merrouche,Y.; Le Bail,N.; Alakl,M.K. (Cancer Chemother Pharmacol, 1995)